Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) has provided a corporate update and strategic roadmap for its barium and iodine contrast media projects, emphasizing efforts to secure a vertically integrated supply chain for medical imaging drugs. The global contrast media market is projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033, according to Research Contrast, highlighting the importance of reliable supply sources.
The company is advancing two bankable feasibility studies (BFS): the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project. The Frances Creek barium project, now in the BFS phase, hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical-grade barium sulfate, with an average grade of 98.8% BaSO4, exceeding pharmaceutical grade requirements. Recent testing confirmed purity, and the company expects to deliver the BFS in the second half of 2026 after completing geotechnical drilling.
Voyageur has completed product development for five Health Canada-approved barium products with Alberta Veterinary Laboratories and generated approximately C$32,000 in initial contrast product sales, establishing commercial validation. The company is building a customer network in Canada and exploring international opportunities in Latin America, the Middle East, North Africa, and Asia-Pacific. The FDA regulatory pathway for barium and iodine contrast media is expected to follow an 18- to 24-month review process, with potential U.S. barium market entry as soon as mid-2027 to late-2027. Voyageur commenced the FDA approval process in February 2026 via the 505(b)(2) regulatory pathway and expects FDA feedback in Q1 2026. The company also plans to advance a generic iodine FDA license in the second half of 2026.
The iodine strategy includes the Bayer Iodine Project, anchored by a US$2.35 million funding commitment subject to BFS completion. Bayer may provide capital financing for production under an offtake-linked arrangement, with Voyageur operating the project. All intellectual property remains owned by Voyageur. Additionally, Voyageur is independently advancing a prefeasibility study for iodine contrast media production, integrating the Mueller iodine extraction process with the Streamline drug manufacturing platform, targeting 35 million doses per year from iodine-rich brine sourced from U.S. oil and gas operations.
Voyageur is engaging a global engineering company to complete the two BFS, positioning itself to become the only vertically integrated manufacturer of barium and iodine contrast media globally. The company is reviewing financial options to fund capital expenditures, targeting construction commencement in 2027. The strategic initiatives aim to maximize stakeholder value by providing affordable and secure supplies for healthcare authorities worldwide, reinforcing the company's "From Earth to Bottle" value proposition.
